A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

Recruiting now · Phase 1/Phase 2

Conditions studied: Advanced Solid Tumor

In brief

This study investigates the safety and tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of EIK1003 in participants with advanced solid tumors.

Key facts

Study ID

NCT06253130

Run by

Eikon Therapeutics

People needed

156

Starts

2023-12-11

Expected to finish

2027-12-01

Last updated by the study team

2026-06-15

Who can join

Age: 18 and older, up to 89. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Princess Margaret Cancer Centre-University Health Network — Toronto, Ontario, Canada (enrolling)
• Shandong Cancer Hospital — Jinan, Shandong, China (enrolling)
• Princess Alexandra Hospital — Woolloongabba, Queensland, Australia (enrolling)
• Sunnybrook Research Institute — Toronto, Ontario, Canada (enrolling)
• Sun Yat-sen University Cancer Center — Guangzhou, Guangdong, China (enrolling)
• The Fourth Hospital of Hebei Medical University — Shijiazhuang, Hebei, China (enrolling)
• Macquarie University — Sydney, Queensland, Australia (enrolling)
• Advent Health Research Institute — Celebration, Florida, United States (enrolling)
• Sylvester Comprehensive Cancer Center — Miami, Florida, United States (enrolling)
• Cross Cancer Institute — Edmonton, Alberta, Canada (enrolling)
• The University of Arizona Cancer Center — Tucson, Arizona, United States (enrolling)
• Henry Ford Health — Detroit, Michigan, United States (enrolling)
• University of Minnesota-Clinical Research Unit — Minneapolis, Minnesota, United States (enrolling)
• Sarah Cannon Research Institute Health One — Denver, Colorado, United States (enrolling)
• Smilow Cancer Hospital at Yale New Haven — New Haven, Connecticut, United States (enrolling)
• University of Arkansas Winthrop P. Rockefeller Cancer Institute — Little Rock, Arkansas, United States (enrolling)
• Lifespan Cancer Institute — Providence, Rhode Island, United States (enrolling)
• Medical University of South Carolina (MUSC) - Hollings CC — Charleston, South Carolina, United States (enrolling)
• West Cancer Center & Research Institute — Germantown, Tennessee, United States (enrolling)
• Sarah Cannon Research Institue Oncology — Nashville, Tennessee, United States (enrolling)
• University of Michigan Rogel Cancer Center — Ann Arbor, Michigan, United States (enrolling)
• Peninsula and south eastern haematology and oncology group — Frankston, Victoria, Australia (enrolling)
• Karmanos Cancer Institute — Detroit, Michigan, United States (enrolling)
• Mater Cancer Care Centre, Mater Misericordiae Limited — South Brisbane, Queensland, Australia (enrolling)
• Sir Run Run Shaw Hospital Zhejiang University School of Medicine — Hangzhou, Zhejiang, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.